Director Sophie Kornowski filed a Form 4 with the SEC on August 17, 2026, disclosing the acquisition of a stock option grant in Maze Therapeutics, Inc. (NASDAQ:MAZE) dated August 13, 2026.
Key Highlights
- Reporting person: Sophie Kornowski, identified as a Director of Maze Therapeutics, Inc.
- Security acquired: A stock option (right to buy) covering 36,000 shares of Common Stock, acquired on August 13, 2026.
- Exercise price: $27.665 per share, with an expiration date of August 12, 2036.
- Grant cost: The price of the derivative security is listed as $0.
- Vesting schedule: The option vests as to 1/36th of the total award monthly, with the first tranche vesting on September 13, 2026, and subsequent tranches vesting on each monthly anniversary thereafter, subject to continued service.
- Beneficial ownership following transaction: 36,000 derivative securities beneficially owned directly.
Sophie Kornowski Stock Option Award Details at Maze Therapeutics
According to the Form 4 filed on August 17, 2026, Sophie Kornowski, a Director at Maze Therapeutics, Inc., received a stock option grant on August 13, 2026. The transaction code reported is "A," indicating an acquisition. The option covers 36,000 shares of Common Stock and was recorded at a derivative security price of $0, with an exercise price of $27.665 per share.
The filing discloses that the option carries an expiration date of August 12, 2036. As described in the explanation of responses, "The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on September 13, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date." No shares in Table I (non-derivative securities) were reported as acquired or disposed of in connection with this transaction.
Following the reported transaction, Kornowski's total beneficial ownership in derivative securities stands at 36,000 stock options held directly, according to the filing. The Form 4 was signed by Courtney Phillips as attorney-in-fact on August 17, 2026, and was filed as a single reporting person disclosure. No amendment date was indicated, and no foreign trading symbol was listed.
What Was Disclosed
The filing reports a single derivative security acquisition by Director Sophie Kornowski: a stock option to purchase 36,000 shares of Maze Therapeutics Common Stock at $27.665 per share, expiring August 12, 2036, with monthly vesting over 36 months contingent on continued service.




Please wait processing your request...